ASLAN PHARMACEU/ADR (NASDAQ:ASLN) gapped up prior to trading on Tuesday . The stock had previously closed at $3.70, but opened at $5.20. ASLAN PHARMACEU/ADR shares last traded at $2.76, with a volume of 209,148 shares changing hands.
A number of brokerages recently issued reports on ASLN. BTIG Research lowered ASLAN PHARMACEU/ADR from a “buy” rating to a “neutral” rating in a research note on Monday, November 11th. Piper Jaffray Companies upgraded ASLAN PHARMACEU/ADR from a “neutral” rating to an “overweight” rating and set a $8.00 price target on the stock in a research note on Monday. Zacks Investment Research raised ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 price objective on the stock in a report on Monday, November 4th. Finally, HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of ASLAN PHARMACEU/ADR in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. ASLAN PHARMACEU/ADR presently has a consensus rating of “Buy” and an average price target of $4.00.
The company has a 50 day simple moving average of $1.68 and a 200 day simple moving average of $2.48. The company has a debt-to-equity ratio of 1.12, a quick ratio of 3.80 and a current ratio of 1.88. The company has a market capitalization of $122.43 million, a PE ratio of -1.97 and a beta of 3.31.
A hedge fund recently raised its stake in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC raised its position in ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 57.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,100 shares of the company’s stock after buying an additional 6,993 shares during the quarter. FNY Investment Advisers LLC owned approximately 0.06% of ASLAN PHARMACEU/ADR worth $33,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 7.12% of the company’s stock.
ASLAN PHARMACEU/ADR Company Profile (NASDAQ:ASLN)
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Featured Story: What is a balanced fund?
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.